We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
- Authors
Ozdemir Isik, Ozlem; Karadag, Duygu Temiz; Tekeoglu, Senem; Yazici, Ayten; Cefle, Kıvanc; Cefle, Ayse
- Abstract
Hyperimmunoglobulin D syndrome (HIDS) is a rare autoinflammatory disorder with autosomal recessive inheritance. It is caused by specific mutations in the mevalonate kinase gene (MVK). No treatment specific to HIDS has been approved to date; however, nonsteroidal anti‐inflammatory drugs, steroids, colchicine, tumor necrosis factor‐α inhibitors, and anti‐interleukin‐1 treatments are used, based on case reports and observational studies. Herein, we report a case with recurrent fever and arthritis attacks who did not respond to anakinra and was successfully treated with canakinumab. Long‐term remission was achieved without any side effects with 300 mg canakinumab treatment every 4 weeks for 5 years.
- Subjects
MEVALONATE kinase; SYNDROMES; TREATMENT effectiveness; ANTI-inflammatory agents; COLCHICINE; DISEASE remission
- Publication
International Journal of Rheumatic Diseases, 2024, Vol 27, Issue 1, p1
- ISSN
1756-1841
- Publication type
Article
- DOI
10.1111/1756-185X.14857